Cryo Cell International Capital Expenditures (CapEx) Growth & History (CCEL)
Cryo Cell International's capital expenditures (capex) was $230,475 for fiscal 2025.
View full Cryo Cell International company overviewCryo Cell International annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-11-30 | $230,475 | −$2.2M | −90.41% |
| 2024 | 2024-11-30 | $2.4M | −$4.4M | −64.85% |
| 2023 | 2023-11-30 | $6.8M | −$5.3M | −43.80% |
| 2022 | 2022-11-30 | $12.2M | $10.3M | +563.49% |
| 2021 | 2021-11-30 | $1.8M | $1.7M | +1734.69% |
| 2020 | 2020-11-30 | $99,962 | −$562,333 | −84.91% |
| 2019 | 2019-11-30 | $662,295 | $216,132 | +48.44% |
| 2018 | 2018-11-30 | $446,163 | $347,830 | +353.73% |
| 2017 | 2017-11-30 | $98,333 | −$244,649 | −71.33% |
| 2016 | 2016-11-30 | $342,982 | $234,502 | +216.17% |
| 2015 | 2015-11-30 | $108,480 | −$12,037 | −9.99% |
| 2014 | 2014-11-30 | $120,517 | −$229,267 | −65.55% |
| 2013 | 2013-11-30 | $349,784 | $216,246 | +161.94% |
| 2012 | 2012-11-30 | $133,538 | −$372,177 | −73.59% |
| 2011 | 2011-11-30 | $505,715 | $106,818 | +26.78% |
| 2010 | 2010-11-30 | $398,897 | — | — |
Cryo Cell International quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | $32,701 | −$29,707 | −47.60% |
| Q1 2026 | 2026-02-28 | $67,065 | $5,012 | +8.08% |
| Q4 2025 | 2025-11-30 | $67,226 | $58,878 | +705.29% |
| Q3 2025 | 2025-08-31 | $38,788 | −$146,918 | −79.11% |
| Q2 2025 | 2025-05-31 | $62,408 | −$1.7M | −96.44% |
| Q1 2025 | 2025-02-28 | $62,053 | −$395,669 | −86.44% |
| Q4 2024 | 2024-11-30 | $8,348 | −$1.7M | −99.51% |
| Q3 2024 | 2024-08-31 | $185,706 | −$3.1M | −94.36% |
| Q2 2024 | 2024-05-31 | $1.8M | $294,489 | +20.21% |
| Q1 2024 | 2024-02-29 | $457,722 | $82,122 | +21.86% |
| Q4 2023 | 2023-11-30 | $1.7M | $1.7M | +6756.64% |
| Q3 2023 | 2023-08-31 | $3.3M | −$7.9M | −70.72% |
| Q2 2023 | 2023-05-31 | $1.5M | $1.2M | +374.78% |
| Q1 2023 | 2023-02-28 | $375,600 | −$272,037 | −42.00% |
| Q4 2022 | 2022-11-30 | $25,011 | −$254,982 | −91.07% |
| Q3 2022 | 2022-08-31 | $11.2M | $9.7M | +633.74% |
| Q2 2022 | 2022-05-31 | $306,970 | $296,676 | +2882.03% |
| Q1 2022 | 2022-02-28 | $647,637 | $635,659 | +5306.89% |
| Q4 2021 | 2021-11-30 | $279,993 | $232,427 | +488.64% |
| Q3 2021 | 2021-08-31 | $1.5M | $1.5M | +70551.85% |
| Q2 2021 | 2021-05-31 | $10,294 | −$32,973 | −76.21% |
| Q1 2021 | 2021-02-28 | $11,978 | $5,017 | +72.07% |
| Q4 2020 | 2020-11-30 | $47,566 | −$107,390 | −69.30% |
| Q3 2020 | 2020-08-31 | $2,168 | −$96,301 | −97.80% |
| Q2 2020 | 2020-05-31 | $43,267 | −$316,518 | −87.97% |
| Q1 2020 | 2020-02-29 | $6,961 | −$42,124 | −85.82% |
| Q4 2019 | 2019-11-30 | $154,956 | $117,090 | +309.22% |
| Q3 2019 | 2019-08-31 | $98,469 | −$56,124 | −36.30% |
| Q2 2019 | 2019-05-31 | $359,785 | $359,785 | — |
| Q1 2019 | 2019-02-28 | $49,085 | −$204,619 | −80.65% |
| Q4 2018 | 2018-11-30 | $37,866 | −$5,285 | −12.25% |
| Q3 2018 | 2018-08-31 | $154,593 | $103,916 | +205.06% |
| Q2 2018 | 2018-05-31 | $0 | −$1,584 | — |
| Q1 2018 | 2018-02-28 | $253,704 | $250,783 | +8585.52% |
| Q4 2017 | 2017-11-30 | $43,151 | — | — |
| Q3 2017 | 2017-08-31 | $50,677 | $44,319 | +697.06% |
| Q2 2017 | 2017-05-31 | $1,584 | — | — |
| Q1 2017 | 2017-02-28 | $2,921 | −$27,802 | −90.49% |
| Q3 2016 | 2016-08-31 | $6,358 | −$7,391 | −53.76% |
| Q1 2016 | 2016-02-29 | $30,723 | $7,420 | +31.84% |
| Q4 2015 | 2015-11-30 | $53,789 | $26,750 | +98.93% |
| Q3 2015 | 2015-08-31 | $13,749 | −$6,197 | −31.07% |
| Q2 2015 | 2015-05-31 | $17,639 | −$44,868 | −71.78% |
| Q1 2015 | 2015-02-28 | $23,303 | $12,278 | +111.37% |
| Q4 2014 | 2014-11-30 | $27,039 | −$83,364 | −75.51% |
| Q3 2014 | 2014-08-31 | $19,946 | $10,934 | +121.33% |
| Q2 2014 | 2014-05-31 | $62,507 | −$90,569 | −59.17% |
| Q1 2014 | 2014-02-28 | $11,025 | −$66,268 | −85.74% |
| Q4 2013 | 2013-11-30 | $110,403 | $106,263 | +2566.74% |
| Q3 2013 | 2013-08-31 | $9,012 | −$12,139 | −57.39% |
| Q2 2013 | 2013-05-31 | $153,076 | $115,790 | +310.55% |
| Q1 2013 | 2013-02-28 | $77,293 | −$1,948 | −2.46% |
| Q4 2012 | 2012-11-30 | $4,140 | −$50,589 | −92.44% |
| Q3 2012 | 2012-08-31 | $21,151 | −$176,913 | −89.32% |
| Q2 2012 | 2012-05-31 | $37,286 | −$95,492 | −71.92% |
| Q1 2012 | 2012-02-29 | $79,241 | −$150,361 | −65.49% |
| Q4 2011 | 2011-11-30 | $54,729 | — | — |
| Q3 2011 | 2011-08-31 | $198,064 | — | — |
| Q2 2011 | 2011-05-31 | $132,778 | — | — |
| Q1 2011 | 2011-02-28 | $229,602 | — | — |
Cryo Cell International capital expenditures (capex) trends
Over the last five fiscal years, Cryo Cell International's capital expenditures (capex) increased from $99,962 to $230,475, a change of $130,513. The latest reported quarter, Q2 2026, shows $32,701.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cryo Cell International source filings ↗